Biosimilars for anti-VEGF treatment of macular diseases: country and region reports.
Biosimilars for anti-VEGF treatment of macular diseases: country and region reportsBiosimilars can improve patients' access to anti-VEGF treatment for macular diseases, but only if they are approved for local use and are readily available. Anti-VEGF injection. PARAGUAY
Authors
- Mangala Dhanapala (ORCID: https://orcid.org/0000-0001-8092-3873)
- David Yorston (ORCID: https://orcid.org/0000-0001-7259-5320)
- María del Carmen Fernández Cano (ORCID: https://orcid.org/0000-0003-3818-0003)
- Prabhath Piyasena (ORCID: https://orcid.org/0000-0002-0236-0101)
- Rajiv Raman (ORCID: https://orcid.org/0000-0001-5842-0233)
- Meng‐Tian Kang
Institutions
- Sankara Nethralaya (IN)
- Beijing Tongren Hospital (CN)
- Gartnavel General Hospital (GB)
- Universidad Católica Nuestra Señora de la Asunción (PY)
- National Hospital of Sri Lanka (LK)
- Tongren Hospital (CN)
- Anglia Ruskin University (GB)
Publication Details
- Journal
- PubMed
- Published
- 2025-01-01
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.00